Proactive’s Post

Shield Therapeutics plc CEO Anders Lundstrom and CFO Santosh Shanbhag joined Steve Darling from Proactice to share its released an unaudited Q3 2024 trading update revealing $7.2 million in net revenues from ACCRUFeR prescriptions, with an average net selling price of $167 per prescription. Excluding July's summer buying trends, the NSP averaged $192 in Q3, and Shield anticipates maintaining this level into Q4. Shield looks to gain traction, especially in the United States, where it partners with Viatris, deploying a sales force of 100 to promote ACCRUFeR. To support its objective of achieving cash flow positivity by 2025, Shield has expanded its working capital financing with Sallyport Commercial Finance from $10 million to $15 million. Additionally, Shanbhag also noted that steps are being taken to improve Shield’s cash position, including a planned 10% cost reduction and expanded financing from Sallyport, which he... Watch at #Proactive #ProactiveInvestors http://ow.ly/KFbx105Nh15

Zentiva Strengthens Position with Apontis Pharma Acquisition Bid Zentiva has launched a €85M bid to acquire Apontis Pharma, known for its innovative single-pill therapy concept targeting chronic diseases. This move could significantly enhance Zentiva’s product pipeline, especially in the cardiovascular sector, while expanding its footprint across Europe. Key highlights: -Zentiva’s offer of €10 per share represents a substantial premium of 52.9%, highlighting the strong market interest. -Apontis Pharma, branded as “The Single Pill Company,” will become a standalone division under Zentiva, focusing on expanding the single-pill therapy concept as a gold standard in cardiovascular care. -This trend aligns closely with the recent (Sept 2024) ESC guidelines, which emphasize the importance of double and triple fixed-dose combinations in hypertension management. I am curious to see how payers will perceive these fixed-dose combinations in terms of cost-effectiveness, and what impact this will have on pricing and reimbursement. Finally, it will be interesting to follow the marginality Zentiva can achieve in this growing market segment (current data form German market are not super optimisyic). #pharma #healthcare #M&A #portfolioexpansion #innovation #cardiovascular #ESC2024 https://lnkd.in/dMRtq75c

🌍 A Major Win for the Cystic Fibrosis Community! A few months ago Vertex Pharmaceuticals and the NHS reached a pricing agreement, expanding access to transformative CF drugs like Kaftrio. This milestone is deeply personal to me; my cousin Rebecca, who’s battled CF for 30 years, is among those benefiting from Kaftrio. It has truly changed her life. As I work with life sciences leaders and advocate for CF advancements, this progress is particularly inspiring. Here’s to continued breakthroughs in CF care! 💙 #CysticFibrosis #LifeSciences #HealthcareInnovation #VertexPharmaceuticals #Biotechnology

Get an inside look at how Prime Therapeutics is reshaping the PBM landscape!

Get an inside look at how Prime Therapeutics is reshaping the PBM landscape!

Shield Therapeutics plc (AIM:STX, OTCQX:SHIEF) delivered a nearly three-fold increase in its revenues and revealed a strong bank balance as it said it aimed to be cash flow positive in the second half of next year. It ended the year with total sales of $17.5m, up from $6.2m 12 months earlier, buoyed by strong demand for its iron deficiency product, Accrufer, the average selling of which increased by 21% to $145 per prescription. Shield ended 2023 with cash of $13.9m. A generally upbeat statement did come with one caveat: Errors in third-party data reporting have led to a revision in prescription forecasts. Total prescriptions were 77,000.  "The progress made in the market in 2023 has shown us that the opportunity for Accrufer continues to be significant," said CEO Greg Madison. More at #Proactive #ProactiveInvestors #biotech #healthcare #shieldtherapeutics http://ow.ly/tFtW105jhrG

# Only put off until tomorrow what you are willing to die having left undone ## Seize the Opportunity with Corcept Therapeutics and Unlock the Potential of Your HSA! 💪💰 Corcept Therapeutics has been making waves in the healthcare industry with its highly successful sole-marketed drug, Korlym \(mifepristone\). This revolutionary medication, approved for treating Cushing's syndrome, has experienced a tremendous surge in demand over the past few quarters, showcasing its immense potential for investors. 🚀 But that's not all! Corcept Therapeutics is also advancing rapidly in its pipeline development, with a promising set of candidates on the horizon. This signifies a bright future for the company and an incredible investment opportunity for those looking to grow their Health Savings Account \(HSA\) through smart investing. 💼💡 By considering Corcept stock now, you can position yourself to benefit from the successful development and commercialization of future breakthrough medications. Don't miss out on this chance to invest in a company at the forefront of innovative healthcare solutions. Act today to avoid the Fear of Missing Out \(FOMO\) and take control of your financial future! 🏃♀️🏃♂️💼 Remember, investing in healthcare not only promotes your financial well-being but also supports the advancement of life-saving treatments, creating a healthier future for you, your family, and society as a whole. 🌍💙 #hsa #investing #healthcare #health #family #wellness

EraCal Therapeutics AG (“EraCal”), a Swiss biotech start-up company focusing on the fight of obesity, has licensed its main asset to Novo Nordisk for a total amount of EUR 235m in a collaboration and license deal. VISCHER advised EraCal on all legal issues related to the transaction. The VISCHER team included Christian Wyss (pictured) (Partner, Corporate/M&A), Pauline Pfirter (Senior Associate, Corporate/M&A) and Lukas Wendt (Associate, Corporate/M&A). Read the article >> https://lnkd.in/dJmpSh79 #Legalcommunitych #legaladvisor #licensing

This Wednesday, May 22nd, at 12PM EST / 5PM GMT we are hosting an amazing panel with Brenda medina from Kyowa Kirin, Inc.- U.S., Rob Aitchison from 4C, Scott Sawicki, formerly of ADC Therapeutics and Kara Titus of Dragonfly Therapeutics, Inc.. We will discuss clinical vendor management key questions, such as: - why does it cost so much to onboard and qualify clinical vendors? - what can we do, as an industry, to lower the cost of clinical outsourcing? - how to we become more proactive in managing vendor portfolio risk? Come hear the experts weigh in the questions and ask yours. To register, use the link:

🇺🇸📈The stocks with the highest growth over the week in the Russell 2000 index: ⠀   1. Summit Therapeutics Inc. (#SMMT) - +160.23%; 2. PureCycle Technologies, Inc. (#PCT) - +83.75%; 3. Viridian Therapeutics, Inc. (#VRDN) - +56.56%; 4. Petco Health and Wellness (#WOOF) - +56.31%; 5. Mersana Therapeutics, Inc. (#MRSN) - +56.30%. 🇺🇸📉The stocks with the biggest decline over the week in the Russell 2000 index: 1. Fulcrum Therapeutics, Inc. (#FULC) - -62.76%; 2. ModivCare Inc. (#MODV) - -55.88%; 3. Prelude Therapeutics Inc. (#PRLD) - -42.89%; 4. Torrid Holdings Inc. (#CURV) - -39.06%; 5. SelectQuote, Inc. (#SLQT) - -38.23%. #RUT #USA #StockMarket